Establishment Labs (NASDAQ:ESTA) Stock Price Expected to Rise, Stephens Analyst Says

Establishment Labs (NASDAQ:ESTA) had its price objective boosted by research analysts at Stephens from $85.00 to $90.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Stephens’ price objective would suggest a potential upside of 16.66% from the company’s current price.

Other equities analysts also recently issued reports about the stock. Needham & Company LLC boosted their target price on shares of Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Tuesday. Citigroup increased their target price on shares of Establishment Labs from $62.00 to $75.00 and gave the company a “neutral” rating in a research report on Thursday, December 11th. BTIG Research raised their target price on shares of Establishment Labs from $86.00 to $88.00 and gave the company a “buy” rating in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a research report on Monday, December 29th. Finally, Canaccord Genuity Group raised their price objective on Establishment Labs from $72.00 to $85.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $87.00.

Establishment Labs Stock Performance

Shares of ESTA stock opened at $77.15 on Wednesday. The firm has a market cap of $2.24 billion, a price-to-earnings ratio of -44.34 and a beta of 0.99. Establishment Labs has a 52-week low of $26.56 and a 52-week high of $83.31. The company has a quick ratio of 2.10, a current ratio of 3.33 and a debt-to-equity ratio of 15.06. The company’s 50 day moving average is $71.21 and its 200 day moving average is $58.00.

Establishment Labs (NASDAQ:ESTA) last announced its earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.13. The business had revenue of $64.62 million for the quarter, compared to analysts’ expectations of $63.80 million. Establishment Labs had a negative return on equity of 197.22% and a negative net margin of 24.19%.The business’s revenue for the quarter was up 45.2% on a year-over-year basis. During the same quarter last year, the firm earned ($1.19) EPS. On average, sell-side analysts anticipate that Establishment Labs will post -2.41 EPS for the current fiscal year.

Institutional Investors Weigh In On Establishment Labs

Institutional investors and hedge funds have recently modified their holdings of the company. Nantahala Capital Management LLC increased its holdings in Establishment Labs by 11.1% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,973,492 shares of the company’s stock worth $80,893,000 after buying an additional 197,962 shares during the period. Bamco Inc. NY boosted its holdings in shares of Establishment Labs by 30.2% in the 3rd quarter. Bamco Inc. NY now owns 1,181,824 shares of the company’s stock valued at $48,443,000 after acquiring an additional 274,287 shares during the last quarter. Tyro Capital Management LLC increased its stake in shares of Establishment Labs by 1.0% in the third quarter. Tyro Capital Management LLC now owns 1,077,456 shares of the company’s stock worth $44,165,000 after acquiring an additional 10,735 shares during the period. William Blair Investment Management LLC increased its stake in shares of Establishment Labs by 17.6% in the third quarter. William Blair Investment Management LLC now owns 1,017,543 shares of the company’s stock worth $41,709,000 after acquiring an additional 152,299 shares during the period. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Establishment Labs by 117.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock worth $59,145,000 after purchasing an additional 438,206 shares during the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs News Summary

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: Multiple brokerages raised price targets and kept bullish ratings — Canaccord raised its target to $90 and kept a Buy rating, Stephens raised to $90 with an Overweight, Mizuho lifted to $100 with an Outperform, and BTIG moved to $88 with a Buy — reinforcing analyst conviction and upside. Analyst Price Target Raises (Benzinga)
• Positive Sentiment: Q4 2025 results beat expectations: revenue (~$64.6M) and EPS beat consensus, with year‑over‑year revenue growth (~45%) — results and commentary underpin the recent analyst upgrades. Q4 2025 Earnings Call Summary (Yahoo)
• Positive Sentiment: Management provided 2026 guidance targeting at least 25% revenue growth and emphasized expansion of minimally invasive platforms — a clear growth thesis that supports higher valuation if execution continues. 2026 Revenue Guidance & Platform Expansion (MSN)
• Neutral Sentiment: Company announced a leadership transition framed as supporting the next phase of growth — this is management-level news to monitor for execution risk but not an immediate negative. Leadership Transition (Yahoo)
• Neutral Sentiment: Analyst note roundup summarizes 11 analysts’ views — useful context on street sentiment and target dispersion but adds no single new catalyst. Analyst Roundup: 11 Analysts (Benzinga)
• Negative Sentiment: Market reaction: shares are trading lower today despite the earnings beat, guidance and several price‑target raises — suggests some profit‑taking or skepticism about margins/near‑term profitability. Market Reaction

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.